Cyprotex Expands Bioanalytical Capabilities

Cyprotex has expanded its bioanalytical capabilities within the BioHub site at Alderley Park in the UK to increase its offering to both existing customers and new customers in new markets.

The new instruments include a Waters Xevo G2-S QTof high resolution accurate mass spectrometer (“QTof”), a LabLogic Beta-Ram radiochemical detector and a Waters Atmospheric Pressure Gas Chromatography (APGC) system. This investment enables Cyprotex to improve its services to its existing pharmaceutical customers, as well as unlock future potential in new markets such as the chemical and personal care markets.
 

Assessing the metabolites formed following drug exposure is a key part of the drug development process. The Waters Xevo G2-S QTof mass spectrometer is one of the most advanced instruments for this purpose. By determining the accurate mass of the metabolites it enables more precise structural characterisation to be achieved. The new QTof can also be linked to a LabLogic Beta-Ram radiochemical detector which complements this service allowing detection of radiochemicals and quantification of radiolabelled metabolites formed.

Although the company's current analytical equipment is suitable for the majority of molecules it tests, it is not appropriate for certain classes of compounds and chemicals. As Cyprotex expands into the personal care and chemicals market, an ability to analyse more volatile compounds is required. The company has, therefore, invested in gas chromatography, which is a more appropriate platform for these types of molecules. Another key trend in the market is the preclinical development of large molecules. The QTof can analyse an extended range of molecular weights meaning the analysis of larger molecules is more achievable.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the expansion of the bioanalytical facility: "Characterising the structural identity of drug metabolites is a critical part of the drug development process. By investing in the QTof and the radiochemical detector we can now provide a comprehensive service which is appropriate for late stage preclinical development projects required by the regulatory authorities.

“As we expand into new markets we are observing a shift in the requirements for bioanalysis, and we are adapting our business accordingly. We now have a wide range of solutions to cover our differing customers’ needs, allowing us to grow our existing business as well as attract customers from new markets.”